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Respiratory syncytial virus (RSV) remains a major cause of severe respiratory diseases in infants, young children, and the
elderly. However, development of a RSV vaccine has been hampered by the outcome of the infant trials in the 1960s with a
formalin-inactivated RSV preparation. Enhanced lung disease was induced by the vaccination post-RSV exposure. Previous
studies in mice primed with RSV G protein either formulated in adjuvants or delivered by recombinant vaccinia viruses have
indicated that enhanced lung pathology resulted from a Th2-type host immune response against the viral G protein. However,
in the present report, we have demonstrated that vaccination with plasmid vectors encoding either a full-length or a secreted
G protein (DNA-G) clearly elicited balanced systemic and pulmonary Th1/Th2 cytokine responses in mice and did not induce
an atypical pulmonary inflammatory reaction post-RSV challenge in cotton rats. DNA-G immunization also induced marked
virus neutralizing antibody responses and protection against RSV infection of the lower respiratory tract of both mice and
cotton rats. So far, only genetic immunization has been able to induce a balanced Th1/Th2 response with the RSV G protein,
reminiscent of that induced by live RSV. Therefore, DNA-G is a promising immunogen for inclusion in a nucleic acid RSV
vaccine. © 2000 Academic Press
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1INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause
of bronchiolitis and pneumonia in infants and young
children worldwide causing significant morbidity and
mortality (Hall, 1994). The importance of RSV as a respi-
ratory pathogen has also been recognized in the elderly
(Falsey and Walsh, 1992). Thus, development of a safe
and effective RSV vaccine remains a high public health
priority. Protection against RSV is contingent on the in-
duction of virus neutralizing antibody responses against
the two surface glycoproteins of the virus. The conserved
fusion (F) protein has been shown to be a cross-protec-
tive antigen against both RSV A and B subtypes (Johnson
and Collins, 1988; Johnson et al., 1987a). The G protein is
highly glycosylated membrane protein thought to be
esponsible for viral attachment to the host cell. It is
onserved within each RSV subtype and confers sub-
ype-specific protection only (Johnson et al., 1987b; Wertz
t al., 1985). The addition of the G protein to an F protein-
ased RSV vaccine may enhance its efficacy by eliciting
n anti-G antibody response, providing synergy to the
nti-F antibody response. This would result in a better
imicry of natural immunity. Through alternative initia-
ion of translation, the G protein was found to be pro-
uced in both secreted and membrane-anchored forms
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54n vitro: the function of the secreted form is unknown
Roberts et al., 1994).
The development of an RSV vaccine has been ham-
pered by the observation in the 1960s that vaccination of
infants with a formalin-inactivated RSV (FI-RSV) prepara-
tion not only did not prevent RSV disease but also led to
enhanced pulmonary disease in some vaccinees, even
death, upon RSV infection (Kapikian et al., 1969; Kim et
al., 1969). In the murine model of RSV infection, vaccine-
augmented lung disease was attributed to an imbal-
anced cell-mediated immune response of the Th2 type
(Openshaw, 1995). Specifically, the pattern of pulmonary
cytokine response depends on the nature of the priming
immunogen. Enhanced lung pathology observed in mice
vaccinated with FI-RSV and challenged with live virus is
mediated by CD41 T cells and associated with the local
release of Th2 cytokines (IL-4, IL-5, and IL-10). In con-
trast, immunization with live RSV which elicits a mixed
Th1/Th2 cytokine response dominated by interferon-g
(IFN-g), a Th1 cytokine, does not cause enhanced lung
athology (Connors et al., 1992; Graham et al., 1993;
aris et al., 1996).
In this model, vaccine-enhanced lung disease has
een attributed to a polarized Th2 response against the
SV G protein (Alwan et al., 1993; Hancock et al., 1996;
penshaw et al., 1992; Srikiatkhachorn and Braciale,
997b). Mice primed with either an adjuvanted G protein
r recombinant vaccinia-G vectors (rVV-G) were found to
xhibit strong IL-4 and IL-5 responses, as well as pul-
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RSV. It was suggested that these reactions may be linked
to the failure of the G protein to prime for a MHC class
I-restricted CD81 T-cell response (Alwan et al., 1993;
Nicholas et al., 1990; Srikiatkhachorn and Braciale,
1997a). When immunized with a recombinant vaccinia
virus vector expressing either a mutant G protein con-
taining an immunodominant CTL epitope from the M2
protein of RSV or a combination of the G and M2 pro-
teins, mice developed a strong M2-specific CTL re-
sponse with concomitant down regulation of pulmonary
Th2 cytokines and suppression of eosinophilia upon RSV
infection (Srikiatkhachorn and Braciale, 1997a). These
results suggest that CD81 T cells may play an important
role in the down regulation of Th2 cytokine responses
and suppression of lung eosinophilia during experimen-
tal murine RSV infection.
Recently, rV V-G-enhanced lung pathology in mice was
shown to be dependent on the route of vector adminis-
tration (Bembridge et al., 1998). Scarification, but not
intraperitoneal (ip) injection, induced pulmonary eosino-
philia. However, a systemic Th2 response dominated by
the production of IL-4 and IL-5 was elicited by the vector,
regardless of its route of administration. Although it re-
mains to be determined whether the lung cytokine profile
mirrors the systemic cytokine responses in these ani-
mals, the data suggest that local antigen-presenting
cells (APCs) and lymphoid environment could influence
pulmonary pathology following intranasal RSV challenge.
Elevated pulmonary IL-5 expression and enhanced
lung pathology were more specifically linked to re-
sponses to the secreted form of the G protein in mice
(Bembridge et al., 1998; Johnson et al., 1998). RSV’s ability
to secrete the G protein may thus be a viral strategy to
evade host immune surveillance and a key determinant
of disease pathogenesis. However, regardless of the
secretion state of the G protein, amino acid residues
193–205 in the protein were identified by mutagenesis as
being responsible for enhanced pathology including pul-
monary eosinophilia in mice (Sparer et al., 1998). An
ltered vaccinia-G vector carrying a deletion in the above
egion induced protective immunity in the absence of a
athological response. Conversely, mice vaccinated with
n adjuvanted peptide (184–198)-keyhole limpet hemo-
yanin conjugate showed significant pulmonary eosino-
hilia after challenge with live RSV (Tebbey et al., 1998).
Collectively, these studies support the hypothesis that
the RSV G protein may inherently bias the host immune
responses.
Experimental systems used in the previous studies
might have certain technical limitations. The effect of
purified G protein or peptide on murine Th1/Th2 re-
sponses and enhanced lung pathology post-RSV chal-
lenge depends on the choice of adjuvant and/or carrier.
Another limitation has been the extensive use of recom-
binant vaccinia viruses encoding the G protein and itsmutants. Since vaccinia components may modulate im-
mune responses to the G protein (Smith et al., 1997), it
was desirable to study its immunological properties in
the absence of any other viral components. In this re-
gard, DNA immunization allows for the delivery of a
single antigen and, thus, represents a unique strategy for
elucidating the immunological role of de novo synthe-
sized and properly folded G protein. Genetic immuniza-
tion also has several other advantages for the develop-
ment of an RSV vaccine (Donnelly et al., 1997). They
include its simplicity, the ability to induce long-lasting
immunity via both MHC class I- and MHC class II-re-
stricted pathways of antigen presentation, and the pos-
sibility of modulating the immune response profile (Li et
al., 1998; Pertmer et al., 1996; Ulmer et al., 1996).
We recently showed (Li et al., 1998) that plasmid DNA
encoding the RSV F protein (DNA-F) is as effective as live
RSV in mice, at inducing neutralizing antibody and CTL
responses, protection against infection, and high IFN-g
mRNA expression in lungs post-viral challenge. The goal
of the present study was to determine the suitability of
plasmid DNA encoding the G protein (DNA-G) as a vac-
cine candidate. Toward this, we pursued two specific
objectives: (i) to determine in rodents whether protective
immunity against RSV could be elicited by vaccination
with plasmid DNA encoding the G protein (DNA-G), and
(ii) to compare the pulmonary cytokine profiles and pa-
thology elicited by DNA-G immunization with those in-
duced by live RSV or FI-RSV immunization upon RSV
challenge. We chose these two biologically relevant con-
trols, since live RSV administered by the intranasal (i.n.)
route is not associated with enhanced lung pathology
and elicits the type of response expected from a safe
vaccine. In contrast, FI-RSV has been used as a “gold”
standard formulation for the induction of a deleterious
response. The lung histopathology was evaluated in cot-
ton rats in the present study. These animals are a more
permissive host than mice for infection with human RSV
and are outbred. Hussell et al. (1998) have shown that
the development of vaccine-induced enhanced lung eo-
sinophilia in the mouse model critically depends on
background genes, permissive MHC alleles, or available
T cells in the repertoire. This limitation could be over-
come in the outbred cotton rat model since there is
probably little or no influence of these factors on the
induction of eosinophilia as described in the mice. In
addition, FI-RSV immunization has consistently demon-
strated enhanced lung pathology in cotton rats postin-
tranasal RSV challenge (Prince et al., 1986). We found
that immunization with DNA-G generated significant vi-
rus neutralizing antibody levels and conferred protection
against viral challenge, with balanced lung cytokine ex-
pression and without enhanced lung histopathology
upon RSV challenge. These results demonstrate that
pulmonary Th2 cytokine responses and enhanced lung
pathology are not intrinsic properties of the RSV G pro-
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56 LI ET AL.tein. Currently, the plasmid delivery system is the only
vehicle so far evaluated which can induce a balanced
Th1/Th2 anti-G response, regardless of the route of vec-
tor administration or the form of antigen encoded, anal-
ogous to those seen after i.n. RSV infection. In contrast,
immunization with FI-RSV or the other delivery vehicles
for the G protein always elicited Th2 responses.
RESULTS
In vivo protection by DNA-G vaccination. Plasmid vec-
tors p34M7A and p41M2 encoding the full-length and a
truncated secreted form of the G protein of RSV-type
ATracy, respectively, were constructed. Expression of the
SV G protein in culture supernatants of p34M7A- and
41M2-transfected BHK cells was assessed before pro-
ection studies were performed in vivo. The G protein
as efficiently secreted by p41M2-transfected cells (data
ot shown). In contrast, p34M7A efficiently expressed
he membrane-anchored G protein and only a small
mount of its secreted form (,5% relative to p41M2). A
ow level of secretion was anticipated since the second
nternal initiation codon was unaltered to preserve the
uthentic G gene. To evaluate the protective ability of
34M7A and p41M2, groups of 6 BALB/c mice received
ntramuscular (im) or intradermal (id) injections of 100 mg
of each plasmid, followed by boosts at 6 and 13 weeks.
DNA-G-immunized mice were challenged i.n. with RSV 4
weeks after the second boost and lungs were recovered
4 days later for measurements of virus replication. Re-
gardless of the route of administration, both plasmids
conferred significant and similar protection (6/6 or 5/6)
against primary RSV infection of the lungs compared to
the vector backbone, VR-1012, which did not protect any
immunized mice (0/6) (Table 1). Protection conferred by
the DNA-G vaccination was found to be comparable to
T
Immunoprotective Ability of p34M7A
Immunogen
Form of RSV G
protein encoded
VR-1012 (im)
RSV (i.n.)
FI-RSV (im)
p41M2 (im) Secretory
p41M2 (id) Secretory
p34M7A (im) Full-length
p34M7A (id) Full-length
Note. Mice were immunized with VR-1012 (100 mg), p41M2 (100 mg)
and challenged (i.n.) at Week 17 with RSV (106 PFU). RSV titers were d
a Sensitivity of the assay: 101.70 PFU/g lung.
b The term, fully protected mice, refers to animals with no detectablthat obtained by immunization with live RSV (i.n.) or
FI-RSV (im) (6/6). In addition, a mean infectious virus titerof 4.8 (log10 PFU/g lung) was established in the lungs of
mice immunized with VR-1012 post-RSV challenge. In
subsequent studies, similar protection (6/6) was also
observed in mice, which received only two immuniza-
tions with the DNA-G vectors, and im immunization with
p41M2 was found to confer complete protection against
RSV infection in the absence of cardiotoxin pretreatment
(data not shown).
Humoral immune responses to DNA-G vaccination.
Serum samples obtained 4 weeks after the second plas-
mid boost were analyzed for antibody responses. Both
p34M7A and p41M2, but not VR-1012, induced good
humoral responses (Fig. 1). Levels of anti-G IgG antibod-
ies reached endpoint ELISA titers of 8.3 to 9.4 (log2
41M2 against RSV in BALB/c Mice
virus lung titera
lung) (log10 6 SD)
No. fully protected miceb
No. immunized mice
81 1 0.01 0/6
00 6 0.00 6/6
00 6 0.00 6/6
00 6 0.00 6/6
29 6 0.90 5/6
29 6 0.90 5/6
30 6 1.10 5/6
7A (100 mg), RSV (106 PFU), or FI-RSV (100 mL) at 0, 6, and 13 weeks,
ned in lungs harvested 4 days postchallenge.
in the lungs 4 days post-viral challenge.
FIG. 1. Serum antibody responses to p34M7A and p41M2 immuni-
zation. Mice were immunized im or id with 100 mg of each plasmid and
the vector control VR-1012, respectively, at 0, 6, and 13 weeks. Immune
sera obtained at 17 weeks were analyzed for both anti-G IgG ELISA andABLE 1
and p
Mean
(PFU/g
4.
0.
0.
0.
0.
0.
0.
, p34M
etermiRSV-specific plaque-reduction titers (RSV-PRT). Data are presented as
means 6 SD.
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57RESPIRATORY SYNCYTIAL VIRUS G PROTEIN VACCINEtiter/100). There was no significant difference in the
anti-G IgG antibody levels elicited by p34M7A and
p41M2, regardless of the route of administration. Sub-
stantial in vitro RSV-specific plaque-reduction titers (log2
titers, 6.4–8.0) showed that anti-G antibodies induced by
p34M7A and p41M2 had strong virus neutralizing activity.
Thus, there is a good correlation between in vivo protec-
tion against primary RSV infection and induction of sys-
temic virus neutralizing antibody responses by p34M7A
and p41M2. We also noted that serum anti-G IgG and
RSV-specific plaque-reduction titers following the DNA-G
immunization were comparable to those seen following
vaccination with FI-RSV (im), but lower than those ob-
served after infection with live RSV (i.n.). However these
differences did not result in noticeable differences in
protection (Table 1).
IgG subclass profiles of DNA vaccine responses. We
next determined whether the form of the G protein deliv-
ered by the plasmid vectors and the route of vector
administration would influence the IgG subclass profile
of anti-G responses (Li et al., 1998). Sera obtained from
DNA-G-immunized mice were analyzed for anti-G IgG
isotype titers (Table 2). Both p41M2 and p34M7A, coding
for a secreted G protein and the full-length protein, re-
spectively, elicited significant and comparable levels of
IgG1 (log2 titer/100, 5.6–7.2) and IgG2a (log2 titer/100,
.4–6.1) antibodies after being injected either im or id
IgG1/IgG2a ratio, 1.0–1.6). This pattern resembled that
ollowing RSV infection which induced similar levels of
gG1 (log2 titer/100, 6.5) and IgG2a (log2 titer/100, 7.5)
antibodies (IgG1/IgG2a ratio, 0.9). In contrast, FI-RSV
immunization elicited only IgG1 antibody responses (log2
titer/100, 4.6). We also found that the IgG subclass re-
sponses in mice immunized with DNA-G were not influ-
enced by treatment with cardiotoxin (data not shown).
These findings thus suggest that a balanced immune
TABLE 2
Serum Anti-G Antibody Isotype Response Following Immunization
of BALB/c Mice with DNA-G
Immunogen
Mean anti-RSV G ELISA titer (log2 titer/100 6 SD)
IgG IgG1 IgG2a IgG1/IgG2a
VR-1012 (im) 0.0 6 0.0 0.0 6 0.0 0.0 6 0.0 —
RSV (i.n.) 9.8 6 0.4 6.5 6 1.2 7.5 6 0.6 0.9
FI-RSV (im) 7.1 6 1.0 4.6 6 1.0 0.0 6 0.0 Infinite
p41M2 (im) 8.9 6 1.5 5.7 6 1.7 4.6 6 2.2 1.2
p41M2 (id) 9.4 6 1.2 7.2 6 1.2 4.4 6 1.4 1.6
p34M7A (im) 8.6 6 1.2 5.6 6 1.2 5.7 6 1.5 1.0
p34M7A (id) 8.3 6 1.3 5.9 6 1.5 6.1 6 1.1 1.0
Note. Mice were immunized with VR-1012 (100 mg), p41M2 (100 mg),
p34M7A (100 mg), RSV (106 PFU), or FI-RSV (100 mL) at 0, 6, and 13
weeks. Immune sera were analyzed at Week 17.response reminiscent of that following RSV infection can
be induced in mice with plasmid DNA encoding the Gprotein, regardless of the form of the protein encoded by
the vectors or the route of vector delivery.
Since a murine IgG2a antibody response is usually
associated with a Th1 response and inspection of the G
protein sequence suggested multiple potential H-2d-re-
stricted peptide binding motifs (Engelhard, 1994), it was
possible that a G-specific CTL response might be elic-
ited by the plasmid-encoded G protein in the absence of
the other RSV antigens such as F or M2, known to
contain immunodominant CTL epitopes. DNA-G-immu-
nized mice were analyzed for the presence of splenic,
RSV-specific CTL using persistently RSV-infected BCH4
as target and RSV-negative BC cells as control. Like the
placebo or FI-RSV, p34M7A or p41M2 did not elicit a
detectable CTL response following either im or id admin-
istration. In contrast, mice immunized with RSV or DNA-F
generated CTL responses and these CTL were shown to
be CD81 and MHC class I restricted (data not shown).
hese results are consistent with previous reports that
he G protein delivered either in the context of RSV
nfection or by a recombinant vaccinia virus vector could
ot be processed and/or presented via the MHC class I
athway in H-2d mice or in humans (Alwan et al., 1993;
angham et al., 1986). Similarly, the potential H-2d-re-
stricted CTL epitopes present in the G protein delivered
by the plasmid vectors were not processed and/or pre-
sented with sufficient efficiency. This situation differs
from that of the influenza NP protein, where DNA immu-
nization could elicit a protective CTL response against a
recessive epitope when competition from the immuno-
dominant epitope was removed by mutagenesis of its
MHC class I anchor residues (Fu et al., 1997). Possible
explanations for the lack of CTL induction by the G
protein include its high glycosylation which might con-
tribute to its inefficient processing by the MHC class I
pathway, and the scarcity of G-specific CTL precursors in
the repertoire, although G-dependent killer cell activity
was observed in BALB/c mice immunized with a purified
G protein adjuvanted in QS21 in one study (Hancock et
al., 1996).
Analysis of the splenic cytokine responses to DNA-G
immunization in mice showed strong IFN-g production
following in vitro restimulation (96 h) with irradiated RSV-
infected syngeneic cells. Substantial amounts of IFN-g
were secreted by splenocytes from DNA-G-immunized
mice (18160 pg/mL). However, they were lower than
those obtained from splenocytes of live RSV-immunized
mice (85095 pg/mL) and significantly higher than those
produced by spleen cells from FI-RSV-immunized ani-
mals (155 pg/mL).
mRNA analysis of pulmonary cytokine expression. To
determine if the balanced systemic response to DNA-G
immunization was reflected in the local cell-mediated
response to RSV challenge, we analyzed pulmonary cy-
tokine mRNA expression. Total RNA was extracted from
virus-exposed lungs 4 days post-RSV challenge to mea-
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58 LI ET AL.sure IFN-g, IL-4, and IL-5 message levels, the latter being
f special interest as IL-5 was suggested to critically
ontribute to the eosinophilia associated with enhanced
ung pathology (Graham, 1995; Openshaw, 1995; Waris et
l., 1996). Mice immunized with FI-RSV produced the
ighest IL-4 and IL-5 and the lowest IFN-g mRNA levels
FIG. 2. Mouse lung cytokine mRNA expression profile following
DNA-G immunization. Mice were immunized with plasmid DNA as in
Fig. 1 with 106 PFU of RSV (i.n.) or 100 mL of FI-RSV (im) and challenged
i.n. with RSV (106 PFU) at 17 weeks. Total RNA was prepared from lung
omogenates 4 days postchallenge and subjected to RT-PCR using
L-4-, IL-5-, or IFN-g-specific primers. The amplified products were then
liquid-hybridized to cytokine-specific 32P-labeled probes, resolved on
5% polyacrylamide gels, and quantitated. Data expressed as percent-
age of maximum signal (means 6 SD) were normalized for each
cytokine (i.e., maximum IL-4 and IL-5 signals were observed in mice
immunized im with FI-RSV, and maximum IFN-g signal was detected
following im immunization with p41M2). Three lungs were removed
from each immunization group and analyzed for cytokine mRNA levels
at least twice.
T
Pulmonary Cytokine Res
Immunogen IFN-g IL-4
A. Cytokine
DNA-F (im) 1659 6 158
DNA-G (im) 1586 6 890
RSV (i.n.) 4030 6 107
FI-RSV (im) 344 6 54
B. Cytokine-prod
DNA-F (im) 662 6 187 508 6 46
DNA-G (im) 143 6 35 631 6 154
SV (i.n.) 4147 6 1181 8223 6 1014
I-RSV (im) 879 6 390 31020 6 0
Note. Mice were immunized with DNA-F (100 mg), DNA-G (p41M2) (1
RSV (i.n.) at 17 weeks. ELISA and ELISPOT analyses were performed
RSV-specific responses following subtraction of the total responses with ba
groups. For ELISPOT, the data are presented based on total number of cytokmong all immunized animals (Fig. 2), consistent with the
ystemic and local Th2 responses observed by us and
thers (Doherty, 1994; Graham, 1995; Waris et al., 1996).
n contrast, preimmunization with live RSV generated a
alanced Th1/Th2 cytokine profile, whereas injection
ith VR-1012 resulted in an overall low cytokine re-
ponse following primary RSV infection. Mice immunized
ith p41M2 or p34M7A by either the im or id route
enerated balanced Th1/Th2 cytokine patterns, charac-
erized by a marked IFN-g response and significantly
lower IL-4 and IL-5 responses than those observed with
FI-RSV immunization (P , 0.05, Mann-Whitney test). In
particular, im delivery of p41M2 resulted in a higher
IFN-g response than that following preimmunization with
ive RSV, whereas id delivery of p41M2 and im or id
elivery of p34M7A induced responses comparable to
hose observed following preimmunization with the virus.
hus, the balanced systemic responses observed in
ice primed with DNA-G vectors were concordant with
ulmonary cytokine mRNA expression profiles, regard-
ess of the form of the G protein encoded by the vectors
r their route of delivery.
ELISA and ELISPOT analyses of pulmonary cytokine
xpression. To confirm the pulmonary cytokine mRNA
ata, we selected mice vaccinated im with p41M2 for
urther analysis of lung cytokine production and cytokine-
roducing cells using ELISA and ELISPOT. RSV-specific
esponses were determined using mononuclear cells
solated from mouse lungs harvested 4 days post-i.n.
SV challenge. Actual responses were calculated by
ubtracting the background responses obtained from the
lacebo-immunized/RSV-challenged control groups from
he total responses. For lung cytokine ELISA (Table 3A),
balanced production of both IFN-g and IL-5 was ob-
served in mice preimmunized with live RSV (ratio of IL-5
by ELISA and ELISPOT
IL-5 IL-4/IFN-g IL-5/IFN-g
on (pg/mL)
1155 6 184 0.7
442 6 15 0.3
3674 6 474 0.9
3903 6 744 11.4
cells (No./lung)
108 6 27 0.8 0.2
224 6 127 4.4 1.6
2288 6 991 2.0 0.6
4033 6 821 35.3 4.6
, RSV (106 PFU) or FI-RSV (100 mL), as in Table 2, and challenged with
ung cells 4 days post-RSV challenge. The data shown here representABLE 3
ponses
secreti
ucing
00 mg)
using lckground obtained from placebo-immunized/RSV-challenged control
ine-producing cells recovered from lungs of three mice per group.
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59RESPIRATORY SYNCYTIAL VIRUS G PROTEIN VACCINEto IFN-g: 0.9). In contrast, an over 10-fold lower IFN-g
production was observed with FI-RSV immunization (ra-
tio: 11.4). Reminiscent of live RSV preimmunization, vac-
cination with DNA-F or DNA-G led to balanced response
profiles (ratios: 0.7 and 0.3, respectively). This pattern
was also detected in the ELISPOT assay, measuring the
number of cytokine-producing cells in lungs (Table 3B). A
balanced response was obtained with live RSV preim-
munization (ratio of IL-4 to IFN-g, 2.0; ratio of IL-5 to
IFN-g, 0.6), and im immunization with either DNA-F (ra-
ios: 0.8; 0.2) or p41M2 (ratios: 4.4; 1.6). In contrast, a Th2
esponse dominated by IL-4 and IL-5-producing cells
as observed with FI-RSV immunization (ratios: 35.3;
.6). Collectively, all our pulmonary cytokine data show
hat, comparable to immunization with live RSV or DNA-F,
NA-G vaccination generated a balanced lung Th1/Th2
esponse after i.n. RSV challenge. Predominant Th2 re-
ponses were not detected in mice immunized with
NA-G as determined by several different methods. We
lso found that cardiotoxin pretreatment did not affect
ny of the immune parameters analyzed.
Inflammatory response in cotton rat lungs after RSV
hallenge. To analyze the inflammatory responses to live
SV challenge, cotton rats were immunized im with 10
nd 50 mg/dose of the p41M2 vector which encodes the
ecreted form of the G protein. Cotton rats were not
reated with cardiotoxin prior to DNA immunization, since
ardiotoxin is not applicable for human use and did not,
n the present study, improve DNA-G immunization effi-
iency in mice. These doses of p41M2 were chosen to
chieve approximately 90% reduction in virus lung titers
elative to PBS-immunized/RSV-challenged control ani-
als, consistent with previous observations (G. Prince,
ersonal communication), indicating that inflammatory
esponses in cotton rat lungs are detected with higher
ensitivity when there is a limited degree of RSV repli-
ation.
Table 4 shows the RSV titers in the lungs of cotton rats
mmunized with the DNA-G vector on Day 5 postchal-
TABLE 4
RSV Lung Titers in Cotton Rats at 5 Days Postchallenge
Group
RSV lung titer PFU/g lung
(log10 6 SD)
PBS (200 mL, im) 4.42 6 0.17
RSV (105 PFU, i.n.) 2.00 6 0.00
FI-RSV (200 mL, im) 2.00 6 0.00
DNA-G (10 mg, im) 3.68 6 0.56
DNA-G (50 mg, im) 3.49 6 0.56
Note. Cotton rats were immunized with PBS, RSV, FI-RSV, or DNA-G
p41M2) at 0 and 6 weeks and challenged with RSV (i.n.) at 9 weeks.
irus replication in the lungs was quantitated 5 days postchallenge.enge. At this time, RSV in the lungs was detected at the
eak level. An approximately 5- to 10-fold reduction in
p
airus lung titer was achieved relative to the PBS control
nimals for both doses of DNA-G used. This partial
rotection, which correlated with the induction of a sig-
ificant virus neutralizing antibody response in immu-
ized cotton rats (data not shown), was expected to
acilitate the observation of any inflammatory responses
n the lungs of these animals post-RSV challenge. Lung
ections were scored for inflammation using six areas of
he lung tissue as described under Materials and Meth-
ds. Multiple areas within the lung tissue were examined
n order to define specific types of inflammatory re-
ponses characteristic of those observed following im-
unization with FI-RSV. Indeed, as seen in Fig. 3 (Day 5
nalysis), the most distinctive hallmark of FI-RSV-in-
uced inflammation was interstitial pneumonitis and al-
eolitis. In contrast, other inflammation indices, such as
eribronchiolitis and bronchitis, were found in all groups
nd thus represented generalized inflammation due to
SV infection. Observations made on Days 2 and 10
results not shown) were consistent with those made on
ay 5.
Vaccination with the DNA-G plasmid did not generate
nhanced lung pathology as seen with FI-RSV immuni-
ation. Interstitial pneumonitis and alveolitis were not
bserved under conditions of partial protection where
uch effects would be most sensitively detected. These
esults are consistent with the balanced Th1/Th2 re-
ponse induced by DNA-G.
DISCUSSION
Our results indicate that vaccination with DNA-G leads
o the induction of protective immunity with a balanced
h1/Th2 cytokine expression pattern in mice and the
bsence of enhanced lung pathology after i.n. RSV chal-
enge in the well-recognized cotton rat model of immu-
opotentiation. These findings are analogous to those
een after RSV infection and in contrast to earlier obser-
ations in BALB/c mice immunized with either an adju-
anted G protein or a rVV-G vector (Alwan et al., 1993;
ancock et al., 1996; Openshaw et al., 1992) (Bembridge
t al., 1998; Johnson et al., 1998; Sparer et al., 1998;
rikiatkhachorn and Braciale, 1997a; Tebbey et al., 1998).
ata from these studies suggested that the RSV G pro-
ein induces polarized Th2 responses, and thus pro-
otes atypical pulmonary inflammation following expo-
ure to RSV. In particular, the secreted form of and small
egions in the G protein (193–205, 184–198 that present
pitopes in the context of class II MHC) have been
mplicated in the pathogenesis of vaccine-enhanced
ung disease (Bembridge et al., 1998; Johnson et al.,
998; Sparer et al., 1998; Tebbey et al., 1998). The amino
cid sequence encompassing residues 184–205 is lo-
ated in a conserved domain of the G protein and is also
resent in our RSV isolate. Therefore, differences in the
mino acid sequence in this region of the G protein
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60 LI ET AL.implicated by the Vac-G and synthetic G peptide studies
cannot account for the difference between our results
and those of the others. Although we cannot explain this
difference, a possible explanation might reside in differ-
ences between the delivery systems used, the amount of
G protein delivered, the challenge virus used, and intrin-
sic differences between the inbred BALB/c and outbred
cotton rat models of RSV infection.
Immunization of mice with live RSV or DNA-G vectors
induced balanced Th1/Th2 responses. In contrast, vac-
cination with FI-RSV or the rVV-G constructs elicited Th2
responses. Recombinant vaccinia vectors express the G
protein along with the vaccinia components. A variety of
these proteins are directly involved in viral evasion of
host immune defense and may modulate immune re-
sponses to other antigens (Smith et al., 1997). Also,
immunization with recombinant vaccinia viruses is a
more efficient process than unfacilitated transfection
with purified plasmid DNA. Since these viruses are
highly infectious and capable of replication, they may
deliver a higher dose of the G protein, relative to that
delivered by DNA-G vectors. Low doses of certain anti-
FIG. 3. Lung histopathology profile of cotton rats immunized with D
FI-RSV, or DNA-G at 0 and 6 weeks, and challenged with RSV (i.n.) at 9 w
postchallenge according to the scoring system described under M
istopathology profile 5 days postchallenge.gens have been shown to predominantly induce Th1
responses in mice (Doherty and Coffman, 1996),
i
Dwhereas higher doses of the same antigens induce Th2
responses in these models. In addition, the type and
number of APCs and other immunocompetent cells in-
fected by vaccinia vectors and transfected by DNA-G
may be different.
With respect to purified G protein and peptides previ-
ously tested in mice, their effect on Th1/Th2 responses
may depend on the choice of adjuvants and/or carriers.
Although alum and QS21 are usually inducers of Th2 and
Th1 responses in mice, respectively, immunization of
BALB/c mice with a purified G protein preparation in
either adjuvant induced Th2-dominant responses and
enhanced lung pathology post-RSV challenge (Hancock
et al., 1996). Atypical lung inflammatory reaction was also
observed in mice immunized with a QS21-adjuvanted
peptide (184–198)-keyhole limpet hemocyanin conjugate
in a carrier-dependent fashion (Tebbey et al., 1998).
hese data suggest that specific interactions between G
rotein/peptide and adjuvant/carrier as well as MHC
ight be critical determinants of the immune response.
n addition, the structure of the G protein could have
een altered by the adjuvantation process in these stud-
nd challenged with RSV. Cotton rats were immunized with PBS, RSV,
Lungs were fixed and evaluated for histopathology at 2, 5, and 10 days
and Methods. The data presented (means 6 SD) represent theNA-G a
eeks.es, unlike that of G protein de novo synthesized by
NA-G vector-transfected or RSV-infected cells. Such
s
b
p
t
t
m
b
p
e
I
s
m
m
D
p
p
a
c
a
v
s
e
i
i
o
h
p
j
h
n
t
a
t
e
o
i
o
e
t
A
t
a
b
o
d
o
d
t
e
t
o
T
r
l
l
b
o
r
a
D
i
i
t
a
l
f
n
p
s
b
(
t
1
t
v
t
e
p
c
61RESPIRATORY SYNCYTIAL VIRUS G PROTEIN VACCINEfactors could play an important role in the differences
observed between G protein/peptide-based and genetic
immunization.
Another explanation for the lack of enhanced lung
disease observed with our DNA-G vaccine may relate to
the animal model used. It was clearly shown previously
that G protein-induced eosinophilia in the mouse model
depends on the background genes, permissive MHC
allele, and available T cells in the repertoire. This phe-
notype was observed only in H-2D (BALB/c, B10.D2,
DBA/2) and some H-2B strains (BALB.B and 129 and not
in C57B1/6 and C57B1/10) but not H-2K strains (Hussell
et al., 1998). Furthermore, H-2Dd appears to be a permis-
ive allele for the induction of eosinophilia. It has also
een shown that the potential MHC class II binding
eptides generated from amino acid residues 193–205 of
he G protein seem to be important as mutants lacking
his region failed to induce eosinophilia in a permissive
ouse strain (Sparer et al., 1998). However, it has not
een established that these MHC-restricted eosino-
hilia-inducing motifs in the RSV G protein have any
quivalent in the context of cotton rat or human MHC.
ndeed, G protein has not been reported to induce eo-
inophilia in cotton rats. Therefore, the mouse model
ay not be as appropriate as the outbred cotton rat
odel.
A recent publication reported that immunization with
NA vectors expressing either the RSV F or the RSV G
rotein sensitized BALB/c mice for pulmonary eosino-
hilia following subsequent challenge with RSV (Tripp et
l., 1999). These results were unexpected. Indeed, vac-
ine-enhanced pulmonary eosinophilia has never been
ssociated with the F protein, regardless of the delivery
ehicle used for immunization. Our previous studies con-
istently demonstrated that an optimized DNA-F vector
licited balanced pulmonary cytokine responses follow-
ng RSV challenge (Li et al., 1998). With respect to DNA-G
mmunization, it is difficult to directly compare the study
f Tripp et al. (1999) and our present study, without
aving specific information on their vector, the level of G
rotein expression, and the effect of 25% sucrose coin-
ected with the DNA, and without knowing whether any
umoral immune response was induced by DNA immu-
ization.
Collectively, our data indicate that immunization with
he G protein does not always induce a Th2 response
nd cause enhanced lung pathology following exposure
o RSV. Furthermore, a Th2 response and the induction of
nhanced pulmonary disease are not intrinsic properties
f the RSV G protein regardless of its form. Rather, the
mmune context can fundamentally influence the devel-
pment and differentiation of G-specific T-lymphocyte
ffector functions. This context could be influenced by
he doses of antigen administered, the lymphoid and
PC microenvironment, contribution of immunomodula-
ory components from the delivery system, the nature ofdjuvants and/or carriers used, and the host genetic
ackground. Nevertheless, plasmid DNA vectors are the
nly vehicles that have been used so far to efficiently
eliver the RSV G protein in the absence of other antigen
r adjuvant. They also are the only vehicles which in-
uced balanced anti-G Th1/Th2 responses, regardless of
he route of vector administration or the form of antigen
ncoded, analogous to those seen after i.n. RSV infec-
ion. In contrast, immunization with FI-RSV and all the
ther delivery vehicles for the G protein always elicited
h2 responses. In the mouse model, balanced cytokine
esponses have consistently been associated with the
ack of enhanced lung histopathology post-RSV chal-
enge, whereas a dominant Th2 response has generally
een associated with enhanced pathology. These later
bservations may suggest that factors other than Th2
esponses such as local lymphoid environment could
lso influence pulmonary pathology. In this context,
NA-G vectors could serve as a model to study the
nfluence of other potential immune modulators.
Vaccination with DNA-G leads to marked virus neutral-
zing antibody titers, protection against RSV infection of
he lower respiratory tract, recruitment of a significant
nd balanced pulmonary cytokine response, and the
ack of enhanced pathology post-RSV challenge. There-
ore, DNA-G is a promising immunogen for inclusion in a
ucleic acid RSV vaccine.
MATERIALS AND METHODS
Construction of plasmid vectors encoding the RSV G
rotein from subtype A virus. The mature G protein from
ubtype A RSV contains 298 amino acid residues and
elongs to type II glycoproteins with the transmembrane
TM) domain located near the N-terminus (putative loca-
ion: residues 38 to 66) (Johnson et al., 1987b; Wertz et al.,
985). Since immune responses may be influenced by
he form of the RSV G antigen, we constructed plasmid
ectors encoding either a full-length or a TM domain-
runcated (secreted) protein for DNA immunization. To
ngineer the vector encoding the full-length G protein,
34M7A, a recombinant Bluescript plasmid (RSV G12)
ontaining the full-length cDNA from RSV type ATracy (Du
et al., 1994) was digested with AflIII and EcoRI and
filled-in with the Klenow fragment of DNA polymerase. A
1.23-kb fragment containing the G protein coding se-
quence was gel-purified and ligated to VR-1012 (Vical
Inc., San Diego, CA) previously linearized with EcoRV.
This procedure placed the RSV G full-length cDNA down-
stream of the immediate-early promoter, enhancer, and
intron A sequences of human cytomegalovirus (CMV)
and upstream of the bovine growth hormone (BGH) ter-
mination and poly(A) sequences. For construction of the
plasmid vector encoding a truncated, secreted G protein
lacking the TM domain, p41M2, RSV G12 was digested
with EcoRI, filled-in with Klenow, and redigested with
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62 LI ET AL.BamHI. The DNA segment encoding the truncated G
protein was gel-purified and ligated in the presence of a
pair of 11-mer oligodeoxynucleotides (59-GATCCACT-
CAG-39, 39-GTGAGTCCTAG-59) to VR-1020 (Vical Inc.)
reviously digested with BglII, filled in with Klenow, re-
igested with BamHI, and gel-purified. This procedure
laced the truncated RSV G cDNA (lacking the DNA
egment coding for the 91 N-terminal amino acid resi-
ues including the TM domain) downstream of the im-
ediate-early promoter, enhancer, and intron A se-
uences of human CMV and upstream of the BGH ter-
ination and poly(A) sequences. In addition, 100 bp of
he 59-untranslated region and the signal peptide coding
equence of the human plasminogen activator gene
ere fused in-frame to the 59 end of the truncated G
rotein coding sequence. Although the G protein en-
oded by p41M2 contains a 25 amino acid residue de-
etion at the N-terminus relative to that secreted by RSV,
mmunological properties of the protein should not be
ffected since this region is not associated with or im-
licated in any known function of the molecule. The
DNA fragments in p34M7A and p41M2 were confirmed
y sequencing analysis.
Preparation of formalin-inactivated RSV. In brief, Hep-2
ells were grown in 225-cm2 flasks in minimum essential
edium No. 5 (MEM-5) with 10% FBS and antibiotics. The
ells were incubated at 37°C with a 5% CO2 atmosphere.
When the cells were ;80% confluent the cell monolayers
were washed with 20 mL of serum-free MEM-5. The
Hep-2 cells were then infected with RSV-Bernett at a
median of infectivity of 0.01 in serum-free MEM-5. This is
the same strain of RSV used to make the original FI-RSV
vaccine and was supplied by Dr. P. A. Piedra (Baylor
College of Medicine, Houston, TX). After 4 days the
medium was removed and clarified at 1800 g [r av] for 10
in at 4°C. Formalin was added to the clarified medium
t a final dilution of 1:4000 and the formalin treatment
as carried out for 3 days at 37°C. The formalin-treated
irus suspension was then clarified at 1800 g [r av] for 10
min at 4°C. This clarified formalin-treated virus was ul-
tracentrifuged using a 50.2 Ti rotor at 23,000 rev/min
(50,000 g [r av] for 40 min at 4°C. The supernatant was
discarded and the pellet resuspended in 1/25 of the
original starting material volume in serum-free MEM-5.
This 25X material was compounded with 4 mg/mL of
aluminum phosphate overnight at room temperature. The
adjuvanted material was then pelleted by spinning at
2800 rev/min. The pellet was then resuspended to 14
volume in serum-free MEM containing 0.1% benzetho-
nium chloride. A typical preparation would contain 10–16
ng/dose of RSV F protein.
Immunization and RSV challenge. Plasmid DNA was
purified through double CsCl centrifugation. For intra-
muscular immunization, tibialis anterior muscles of
BALB/c mice (male, 6–8 weeks old) (Jackson Lab., Bar
Harbor, ME) were bilaterally injected with 2 3 50 mg (1mg/mL in PBS) of either p34M7A or p41M2. Five days
rior to DNA injection, the muscles were treated with 2 3
0 mL (10 mM in PBS) of cardiotoxin (Latoxan, France) to
ncrease DNA uptake and enhance immune responses
Davis et al., 1994). The animals were boosted with the
ame dose of plasmid DNA 6 and 13 weeks later. Mice
ere also immunized with DNA-G without the cardio-
oxin pretreatment step. For intradermal (id) immuniza-
ion, 100 mg of the plasmid DNA (2 mg/mL in PBS) was
njected near the base of the tail and boosted 6 and 13
eeks later. Control mice were immunized im with the
ector backbone (VR-1012), intranasally with 106 plaque
forming units (PFU) of a clinical RSV strain of the A2
subtype kindly provided by Dr. B. Graham (Vanderbilt
University) (Graham et al., 1988), or im with a FI-RSV
vaccine similar to that used for the 1960’s trials (Kapikian
et al., 1969; Kim et al., 1969). Four weeks after the third
mmunization, mice were challenged i.n. with 106 PFU of
the same RSV A2 strain. Lungs were asceptically re-
moved 4 days later, weighed, and homogenized in 2 mL
of complete culture medium for the measurements of
RSV PFU (Prince et al., 1978).
Immunogenicity studies. Immune sera were analyzed
for anti-RSV G antibody titers (IgG, IgG1, and IgG2a,
respectively) using ELISAs, and for RSV-specific plaque-
reduction titers. Highly purified native RSV-G protein was
obtained from viral extracts using a multistep process. In
brief, viral glycoproteins were first separated from cell
components and other viral proteins using a mixed-ion
support. Secondly, the abundance of O-linked oligosac-
charides on RSV-G provided a basis for affinity purifica-
tion from the viral glycoprotein fraction with a lectin
(jacalin) affinity column, which specifically recognizes
O-linked oligosaccharides. Any residual RSV-F protein
was removed by immunoaffinity chromatography using
an anti-RSV-F monoclonal antibody. The final RSV-G
preparations were highly purified and did not contain
host-cell proteins or other RSV proteins as judged by
monitoring each step of the purification with immunoblot-
ting and ELISA assays. ELISAs were performed with G
protein-coated microplates (100 ng/mL) using 2-fold se-
rial dilutions of immune sera. Goat anti-mouse IgG anti-
body conjugated to alkaline phosphatase (Jackson Im-
munoResearch, Mississauga, Ontario, Canada) was
used as secondary antibody. For the measurement of
IgG1 and IgG2a antibody titers, the secondary antibodies
were monospecific sheep anti-mouse IgG1 (Serotec, To-
ronto, Ontario, Canada) and rat anti-mouse IgG2a
(Zymed, San Francisco, CA) antibodies conjugated to
alkaline phosphatase, respectively. Plaque-reduction ti-
ters were measured by a standard technique (Prince et
al., 1978). The RSV-specific plaque-reduction titer was
defined as the serum dilution yielding 60% reduction in
plaque number. Both ELISAs and plaque-reduction as-
says were performed in duplicate and average values
are reported.
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63RESPIRATORY SYNCYTIAL VIRUS G PROTEIN VACCINECTL studies. Splenocytes (2.5 3 106 cells/mL) from
mice immunized with the placebo, DNA-G, RSV, DNA-F,
or FI-RSV were incubated in complete RPMI containing
10 U/mL IL-2 and 2.5 3 106 cells/mL g-irradiated (3000
ad) syngeneic splenocytes which had been infected
ith 1 PFU/cell RSV for 2 h at 37°C. After 5 days of
ulture, cells were washed and incubated (4 h/37°C) at
arying effector-to-target ratios with 2 3 103 51Cr-labeled
arget cells (persistently RSV-infected BCH4 fibroblasts)
Fernie et al., 1981). Uninfected BALB/c fibroblasts (BC
ells) served as a control. Spontaneous and total chro-
ium releases were measured in supernatants of target
ells suspended in medium or 2.5% Triton-X 100. The
ercentage of specific lysis was calculated as (counts 2
pontaneous counts)/(total counts 2 spontaneous
ounts) 3 100. Results are reported as mean specific
ysis from triplicate assays. Each experiment was per-
ormed three times. Blocking studies with anti-CD8, anti-
D4, anti-MHC class I, and anti-MHC class II antibodies
ere done to determine phenotype and MHC-restriction
pecificities of CTL as described (Li et al., 1998).
Analysis of cytokine mRNA expression in the lungs.
our days post-RSV challenge, lungs were removed and
mmediately frozen in liquid nitrogen. Total RNA was
repared from lungs homogenized in TRIzol/b-mercap-
toethanol by chloroform extraction and isopropanol pre-
cipitation. RT-PCR was carried out using IL-4-, IL-5-, or
IFN-g-specific primers (CloneTech, Mississauga, On-
ario, Canada). Based on studies of PCR linearity in
imilar mice, IL-4 and IL-5 cDNAs were amplified for 25
ycles, whereas IFN-g cDNAs were amplified for 30
cycles. The amplified products were then liquid-hybrid-
ized to cytokine-specific 32P-labeled probes (CloneTech),
esolved on 5% polyacrylamide gels, and quantitated by
canning of the radioactive signals in the gels. Three
ouse lungs from each treatment group were analyzed
n triplicates and each lung sample was analyzed two to
hree times.
Analysis of lung cytokine expression by ELISA and
LISPOT. To determine the amount of RSV-specific cyto-
ine production by mononuclear cells in lungs, single
ell suspensions were made 4 days post-RSV challenge
s described (Pollard and Lipscomb, 1990) and pooled
rom three immunized mice per group. Viable mononu-
lear cells were isolated on Lympholyte (Cedarlane Lab-
ratory, Hornby, Ontario, Canada) and plated at 3 3
06/well in 24-well plates in 2 mL complete RPMI me-
ium. Over 90% of the cells thus plated in cultures were
cells as per flow cytometric analysis. The culture su-
ernatants were collected 24 h later at 37°C for IFN-g
and IL-5 measurements by ELISA using anti-IFN-g and
anti-IL-5 mAbs (XMG1.2, TRFK4, TRFK5, PharMingen,
Mississauga, Ontario, Canada, and RMMG-1, Biosource,
Camarillo, CA). All assays were performed in duplicates.To quantitate RSV-specific cytokine-producing cells in
lungs, 96-well plates were coated with anti-IFN-g, anti-IL-4, or anti-IL-5 mAbs (R4.6A2, XMG1.2, 11B11, BVD6-
24G2, TRFK4, TRFK5, PharMingen, and RMMG-1, Bio-
source) and blocked with BSA. Single lung cell suspen-
sions were made 4 days post-RSV challenge, pooled
from three immunized mice per group, applied to the
plates at 3 3 105, 3 3 104, and 3 3 103 cells/well,
espectively, and incubated at 37°C in 200 mL/well com-
lete RPMI medium. Seventeen hours later, the cells
ere discarded from the plates, which were then incu-
ated with the appropriate biotinylated anti-cytokine an-
ibody (PharMingen) overnight at 4°C, followed by devel-
pment with extravidin-alkaline phosphatase and BCIP/
BT (Sigma, St. Louis, MO). Spots corresponding to
ytokine-producing cells were counted using a stereomi-
roscope (Leica MS5, Heerbrugg, Switzerland). All as-
ays were performed in triplicates.
Statistical analyses. Data were not normally distrib-
ted and were therefore analyzed using the nonparamet-
ic Mann-Whitney test (SigmaStat software, Jandel Sci-
ntific Software, Guelph, Ontario, Canada). Fisher’s exact
est was used to analyze protection data. Comparisons
ere made at a significance level of 0.05 (P , 0.05).
Lung histopathology evaluation of DNA-G in cotton
ats. It was previously demonstrated that cotton rats
mmunized with FI-RSV developed enhanced lung histo-
athology following RSV challenge (Murphy et al., 1990).
n these animals, there was an approximately 90% re-
uction in the number of infected cells compared to
ontrol unimmunized, RSV-challenged animals. Thus, to
valuate the lung histopathology induced by DNA-G im-
unization, we injected cotton rats (Sigmodon hispidus)
ith two doses of p41M2, encoding a secreted G protein,
iming for a 90% reduction in virus lung titer following
SV challenge. Tibialis anterior muscles of 12 cotton
ats/group were bilaterally injected with either 2 3 5 or
3 25 mg (in 200 mL PBS) of p41M2. The animals were
oosted similarly 6 weeks later. Cotton rats in the control
roups were immunized either im with PBS, i.n. with 105
PFU of RSV/Long strain, or im with the FI-RSV prepara-
tion (200 mL) supplied by Dr. G. Prince (Virion Systems,
ockville, MD). Three weeks after the second immuniza-
ion, the animals were challenged i.n. with 105 PFU of the
same RSV Long strain. Lungs were asceptically removed
2, 5, and 10 days later (4 lungs/group/day). In each
animal, half of the lung was used for the measurements
of RSV PFU as previously described and the other half
was fixed by airway perfusion with PBS-buffered forma-
lin. Hematoxylin and eosin-stained paraffin-embedded
sections were prepared from the fixed lungs. Individual
slides were read blindly in random order and scored
using the following criteria:
Peribronchiolitis/perivasculitis: Scores 0–4 describe
the degree of inflammatory cell (generally lymphocytes)
infiltration around the periphery of bronchioles and ves-
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64 LI ET AL.sels, ranging from “fewer than 5 inflammatory cells” to
“over 15 layers of inflammatory cells.”
Interstitial pneumonitis: Scores 0–4 correspond to the
degree of alveolar wall thickening, ranging from “no
thickening” to “thickening of over 25% of alveolar walls.”
Alveolitis: Scores 0–4 indicate the degree of inflamma-
tory cell (polymorphonuclear leukocytes, PMN, and mac-
rophages) infiltration within the alveolar spaces, ranging
from “no inflammatory cells” to “inflammatory cells in over
50% of alveolar spaces.”
Bronchitis: Scores 0–4 correspond to the number of
PMN infiltrates per bronchus, ranging from “no PMN” to
“over 500 PMN.”
Peribronchiolar PMN: Scores 0–4 describe the degree
of PMN infiltrate surrounding bronchioles, ranging from
“no PMN” to “over 500 PMN.”
Slides were uncoded after being scored and analyzed
using a one-way ANOVA (SigmaStat) model at a signifi-
cance level of 0.05 (P , 0.05).
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